HK Stock Movement | CLOUDBREAK-B (02592) Plunged Nearly 15% as CBT-199 Ophthalmic Drug Candidate Files IND Application in the U.S.

Stock News2025-12-16

CLOUDBREAK-B (02592) saw a sharp decline of nearly 15%, extending its retreat to over 40% since December 5. Notably, the stock had surged significantly from November 21 to December 4, doubling in just 10 trading sessions. As of press time, the stock was down 11.59% at HK$4.96, with a turnover of HK$6.78 million.

On the news front, CLOUDBREAK announced that on December 15, its wholly-owned subsidiary, ADS Therapeutics LLC, submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for CBT-199, a potential best-in-class ophthalmic drug candidate developed by the group. CBT-199 has been undergoing safety and tolerability assessments in preclinical animal studies since June 2023, with the findings expected to support future clinical trials.

Additionally, it is worth noting that on January 3, two cornerstone investors of CLOUDBREAK-B will see their lock-up shares become tradable.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1142110567?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-16 10:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1142110567","market":"fut","top_or_hot":-1,"title":"HK Stock Movement | CLOUDBREAK-B (02592) Plunged Nearly 15% as CBT-199 Ophthalmic Drug Candidate Files IND Application in the U.S.","media":"Stock News","content":"<p>CLOUDBREAK-B (02592) saw a sharp decline of nearly 15%, extending its retreat to over 40% since December 5. Notably, the stock had surged significantly from November 21 to December 4, doubling in just 10 trading sessions. As of press time, the stock was down 11.59% at HK$4.96, with a turnover of HK$6.78 million.</p>\n<p>On the news front, CLOUDBREAK announced that on December 15, its wholly-owned subsidiary, ADS Therapeutics LLC, submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for CBT-199, a potential best-in-class ophthalmic drug candidate developed by the group. CBT-199 has been undergoing safety and tolerability assessments in preclinical animal studies since June 2023, with the findings expected to support future clinical trials.</p>\n<p>Additionally, it is worth noting that on January 3, two cornerstone investors of CLOUDBREAK-B will see their lock-up shares become tradable.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Stock Movement | CLOUDBREAK-B (02592) Plunged Nearly 15% as CBT-199 Ophthalmic Drug Candidate Files IND Application in the U.S.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Stock Movement | CLOUDBREAK-B (02592) Plunged Nearly 15% as CBT-199 Ophthalmic Drug Candidate Files IND Application in the U.S.\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-16 10:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CLOUDBREAK-B (02592) saw a sharp decline of nearly 15%, extending its retreat to over 40% since December 5. Notably, the stock had surged significantly from November 21 to December 4, doubling in just 10 trading sessions. As of press time, the stock was down 11.59% at HK$4.96, with a turnover of HK$6.78 million.</p>\n<p>On the news front, CLOUDBREAK announced that on December 15, its wholly-owned subsidiary, ADS Therapeutics LLC, submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for CBT-199, a potential best-in-class ophthalmic drug candidate developed by the group. CBT-199 has been undergoing safety and tolerability assessments in preclinical animal studies since June 2023, with the findings expected to support future clinical trials.</p>\n<p>Additionally, it is worth noting that on January 3, two cornerstone investors of CLOUDBREAK-B will see their lock-up shares become tradable.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02592","symbol_name":"拨康视云-B","start_time":0,"source_url":"","article_id":"1142110567","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1142110567","pubTimestamp":1765852217,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CLOUDBREAK-B (02592) saw a sharp decline of nearly 15%, extending its retreat to over 40% since December 5. Notably, the stock had surged significantly from November 21 to December 4, doubling in...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02592":"拨康视云-B","BK1161":"生物科技","BK4090":"商品化工","CBT":"卡博特"},"translate_title":"港股动向|CLOUDBREAK-B(02592)重挫近15%，因CBT-199眼科候选药物在美递交IND申请。","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CBT":1,"02592":1},"content_text":"CLOUDBREAK-B (02592) saw a sharp decline of nearly 15%, extending its retreat to over 40% since December 5. Notably, the stock had surged significantly from November 21 to December 4, doubling in just 10 trading sessions. As of press time, the stock was down 11.59% at HK$4.96, with a turnover of HK$6.78 million.\nOn the news front, CLOUDBREAK announced that on December 15, its wholly-owned subsidiary, ADS Therapeutics LLC, submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for CBT-199, a potential best-in-class ophthalmic drug candidate developed by the group. CBT-199 has been undergoing safety and tolerability assessments in preclinical animal studies since June 2023, with the findings expected to support future clinical trials.\nAdditionally, it is worth noting that on January 3, two cornerstone investors of CLOUDBREAK-B will see their lock-up shares become tradable.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1142110567","isCrawlerRequest":true}